Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Indeed, patients who were not supplemented with vitamin D showed lower irisin levels than controls and patients performing the supplementation.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All PWS children were on growth hormone (GH) treatment from at least 12 months, at a dosage ranging from 0.025 to 0.035 mg/kg/day.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Full studies

The genetic background and vitamin D supplementation can affect irisin levels in Prader-Willi syndrome

Study design awaiting verification · Journal of Endocrinological Investigation · 2021

Original publication title

The genetic background and vitamin D supplementation can affect irisin levels in Prader: Willi syndrome

M. F. Faienza; G. Brunetti; G. Grugni; D. Fintini; A. Convertino; P. Pignataro; A. Crinò; S. Colucci; M. Grano

© The Author(s) 2021

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.

An extract from the source publication. Read it in context.

At a glance

Study background

What background does the paper provide?

Prader: Willi syndrome (PWS) is a rare genetic disease with distinctive clinical symptoms that critically impair patients’ quality of life. PWS arises because of the lack of expression of genes located on the paternal chromosome 15q11.2: q13. Three main genetic mechanisms have been recognized in determining PWS: interstitial deletion of the proximal long arm of chromosome 15 (del15q11: q13) (DEL15), maternal uniparental disomy of chromosome 15 (UPD15), and imprinting defects [1]. The main features of the PWS phenotype are broader, and include neonatal hypotonia, poor feeding and initial failure to thrive, followed by hyperphagia and early childhood-onset obesity (if uncontrolled), multiple endocrine abnormalities (including growth hormone deficiency (GHD) and hypogonadism], motor development problems, dysmorphic features, cognitive impairment, and behavioral issues [2]).

Notably, PWS patients also show bone impairment. In detail, prepubertal PWS children display normal bone mineral density (BMD) (if adjusted for the reduced height) [3Not reported5], but in adolescence and adulthood, they presented decreased total BMD and bone mineral content (BMC) possible, because they did not achieve bone mineral accrual, also due to pubertal delay/hypogonadism [6Not reported9]. Consequently, osteoporosis is predominant in PWS individuals, who also have other orthopedic complications related or worsened by weight gain, including scoliosis, kyphosis, hip dysplasia, flat feet, genu valgum and fractures [8, 10].

Recently, researchers have shown an increased interest on irisin, a myokine primarily secreted by skeletal muscle, involved in bone, adipose tissue and brain homeostasis. In detail, in young mice irisin injection mimicked the effects of exercise by increasing cortical bone mass and strength [11]. In hindlimb unloaded mice, intermittent administration of irisin prevented bone loss [12]. Interestingly, the myokine is also known to determine the browning of white adipose tissue [13] and to work as an adipokine as it is secreted by the same tissue [14].

Additionally, it has also been reported that irisin may have an effect on certain brain functions, and consequently it is involved in cognitive impairment and in neurodegenerative disease [15, 16]. These issues prompted some authors to evaluate irisin levels in adult PWS patients. In detail, Hirsch et al. found increased amounts of salivary irisin in obese PWS with respect to non-obese controls, whereas the plasma levels of irisin did not change significantly between the two groups [17, 18].

Recently, Mai et al. also reported that PWS patients and controls have similar circulating irisin levels [19]. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients in relation to the genetic background, metabolic profile, cognitive impairment and bone status.

Source: Introduction Source: Introduction

Study methods

What methods does the paper describe?

Patients

Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were included in this study. All patients showed the typical PWS clinical phenotype [20]. Genetic investigation was performed in all PWS patients, and 48 of them had DEL15 (32 adults and 16 children), while UPD15 was found in the remaining individuals (20 adults and 10 children).

All PWS children were on growth hormone (GH) treatment from at least 12 months, at a dosage ranging from 0.025 to 0.035 mg/kg/day. Among PWS adults, 6 out of the 52 subjects presented a severe degree of GHD, according to a GH response to GHRH plus arginine less than 4.2 ng/ml [21], and received GH therapy at a mean dose of 0.23 mg/day. At all ages, the GH dose was adjusted to maintain serum total IGF-I within 2 SD from an age-matched reference value to avoid overdosing.

At the time of the study, 10 females and 1 male underwent sex steroid replacement treatment.

As controls, we evaluated a group of 26 children (17 females, mean age 9.4 ± 3.29 years), referred to our hospital for minor surgery or electrocardiographic screening, and 54 normal weight adults (26 females, mean age 36.5 ± 12.5 years) enrolled on a voluntary basis.

PWS and control children performed an average of 2 h per week of school sports, whereas adult PWS and controls about 3 h per week. Four out of 26 PWS children (15%) and 26 out of 52 PWS adults (50%) were on vitamin D supplementation at the moment of the study [cholecalciferol mean dosage: children 500 UI/daily (12.5 mcg/daily); adults 800 UI/daily (20 mcg/daily)].

Exclusion criteria from the study for both patients and controls were the use of mineral and vitamin supplements, except for vitamin D, the presence of chronic diseases with a possible impact on bone metabolism (e.g., hypothyroidism or hyperthyroidism, Cushing’s syndrome, celiac disease, anorexia nervosa, etc.), the use of medications affecting bone turnover, e.g., corticosteroids, and fractures in 6 months preceding the study. Five adult PWS patients had a history of previous post-traumatic fractures at different sites (ankle, ulna, radio, malleolus, fibula, and phalanges).

None of the PWS pediatric patients experienced fractures.

No patient had previously undergone bariatric surgery.

Written informed consent was obtained from all the legal guardians, and from the patients when applicable, prior to inclusion. All procedures were approved by local institutional review boards.

Anthropometric measurements

All patients underwent a general clinical examination, anthropometric measurements (height in cm, weight in kg) and, for the pediatric age, data were plotted on Italian growth charts and computed as percentiles and SDS [22]. BMI was defined as weight in kilograms divided by the square of height in meters. The international standards for sex: and age-specific BMI percentiles were used for subjects aged 2 to 18 years [22]. BMI standard deviation score (SDS) was derived from the published Center for Disease Control and Prevention (CDC) standards [23].

The BMI cut-off point of > 2 SDS was used to define obesity, and between 1.4 and 2 SDS to define overweight for individuals < 18 years of age. Considering adult age, we considered as obese, overweight and normal-weight those subjects with a BMI > 30, in the range of 25 to 30 and < 25, respectively (NIH). The pubertal and genital stages were assessed according to the Tanner criteria [24].

Biochemical measurements

Blood samples were drawn under fasting conditions, centrifuged, and stored at − 80 °C until required. Blood glucose, insulin, total cholesterol (TC), high (HDL) and low (LDL) density lipoprotein cholesterol, triglycerides (TG), were measured after overnight fasting in all subjects, using standard methods. Values of TC, LDL, HDL, and TG were considered in the normal range if within the 5th and the 95th percentile. Calcium, phosphorus and alkaline phosphatase (ALP) concentrations were measured by the nephelometric method. Serum active intact parathyroid hormone (PTH) and 25(OH) vitamin D were measured by immunological tests based on the principle of chemiluminescence using commercial kits (Liaison assay; DiaSorin, Stillwater, Minnesota, USA).

Osteocalcin serum concentration was measured by enzyme immunoassay (IBL International GmbH, Hamburg, Germany). Irisin levels were assessed using a commercially available kit (AdipoGen, Liestal, Switzerland). Insulin resistance was assessed calculating the homeostasis model assessment (HOMA) [25].

Dual-energy X-ray absorptiometry (DXA)

Bone mass of the anterior: posterior lumbar spine (L1: 4) and the total body (TB) was measured by DXA using a Hologic QDR Discovery, and the APEX-system software version 13.3 (Hologic Bedford, MA) with fan beam in array mode. The measurements were performed using standard positioning techniques. Quality control scans were performed daily using a simulated L1: 4 lumbar spine phantom. The lumbar spine DXA scan were analyzed to generate measures of L1: L4 vertebral areal BMD (LSBMD, g/cm2), bone mineral content (LSBMC, g), spine volumetric BMD (LSBMAD, g/cm3) lumbar spine Z score (LSBMD Z score, SDS) [26Not reported28].

Total body scans were obtained to estimate fat mass (FM%), fat free mass (FFM%) expressed as percentage of total body weight (bone mass with the skull excluded from analysis (total body less head, TBLH). Bone variables included BMD (TBLH BMD, g/cm2), BMC (TBLH BMC, g); BMD were normalized for height (TBLH BMD-Ht, g/cm3) to avoid any influence of growth on bone mass [28].

IQ assessment

Global IQ evaluation was assessed in a subgroup of patients based on age. In details, in pediatric PWS it was used Wechsler Intelligence Scale for Children-IV (WISC-IV, n = 6) [29] or Leiter International Performance Scale (n = 5) [30]. The Wechsler Adult Intelligence Scale-IV (WAIS-IV) was used in 29 PWS adults. This test allowed the calculation of the total intelligence quotient (IQ) through the standardized administration of scales, including verbal subtests to determine the verbal quotient (VQ), and performance subtests to determine performance quotient (PQ) [31].

Statistical analyses

Results are shown as median with interquartiles. The Kolmogorov: Smirnov test was utilized to assess the normality of parameter distribution. Mean values were compared by the unpaired Student t-test in parameters with normal distribution, and linear correlations evaluated with Pearson’s correlation coefficient. Significance was calculated with the Mann: Whitney test and Spearman’s correlation coefficient in parameters with skewed distribution. Multiple regression analyses were applied to identify the relative strength of each biochemical and clinical variable in predicting irisin levels. The Statistical Package for the Social Sciences (SPSS) for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA) was utilized for statistical analysis.

The limit of statistical significance was set at 0.05.

Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods Source: Materials and methods

Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS

Results: Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS

Clinical and biochemical characteristics of PWS patients are reported in Table 1. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml, respectively) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml, respectively) (Fig. 1). A more in-depth analysis showed that the type of genetic alteration in PWS patients affected irisin levels. In fact, both pediatric and adult PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively) (Fig. 2a, b).

Otherwise, pediatric and adult PWS with UPD15 did not display significant differences compared with the controls (Fig. 2a, b). These findings prompted us to evaluate if there were significant differences among clinical, biochemical and bone parameters according to the genetic background.

Table 1

Clinical and biochemical characteristics of study population

Pediatric PWS, N = 26Pediatric controls, N = 26Adult PWS, N = 52Adult controls, N = 54
Auxological parameters
 Gender (male/female)11/159/1722/3028/26
 Age (years)10.86 (6)9.40 (3.29)36.00 (20.00)36.9 (18.5)
 Tanner (I/II/III/IV/V)23/1/2/0/022/2/2/0/00/0/25/25/20/0/0/0/54
 Height SDS− 0.70 (1.68)0.40 (1.21)Not reportedNot reported
 Weight SDS1.00 (1.95)0.53 (0.95)Not reportedNot reported
 BMI25.27 (8.4)23.4 (0.92)35.3 (12.1)§24.5 (2.1)
 BMI-SDS2.03 (1.76)0.30 (0.82)Not reportedNot reported
 FM (g)23,756 (8388)Not reported39,150 (16,311)Not reported
 FM (%)41.05 (12.7)Not reported50.50 (10.50)Not reported
 FFM (g)28,913 (9358)Not reported41,582 (10,181)Not reported
 FFM (%)55.93 (11.4)Not reported49.50 (9.00)Not reported
 Total IQ71.00 (20.00)Not reported57.00 (11.00)Not reported
 Verbal IQ-Not reported58.00 (11.00)Not reported
 Performance IQNot reportedNot reported66.00 (17.00)Not reported
Laboratory parameters
 Total cholesterol (mg/dl)159.9 (45.0)144.3 (18.6)180.0 (52.0)
 LDL: C (mg/dl)94.00 (27.0)78.1 (20.2)119.0 (42.0)
 HDL-C (mg/dl)54.00 (16.00)57.8 (8.6)48.0 (20.0)
 Triglycerides (mg/dl)64.00 (50.00)59.2 (15.4)95.0 (51.0)
 Glucose (mg/dl)78.00 ( 9.00)87.22 (11.35)90.0 (19.0)
 Insulin (mU/l)8.49 (6.71)9.2 (3.8)9.6 (5.51)
 HOMA-index1.61 (1.32)1.62 (0.8)2.15 (1.70)
 Osteocalcin (ng/ml)89.00 (14.35)*38.3 (19.2)19.00 (14.00)
 PTH (pg/ml)43.00 (34.00)19.25 ( 5.1)49.4 (34.3)
 Ca (mg/dl)9.80 (0.70)9.71 (0.40)9.50 (0.60)
 P (mg/dl)4.70 (0.80)4.54 (1.40)3.90 (0.70)
 25 (OH) vitamin D23.17 (6.70)28.8 (9.2)
Bone parameters
 LS-BMD Z score0.58 (1.51)Not reportedNot reported
 LS-BMD T score− 1.10 (0.20)Not reported
 TBLH BMC (g)1415 (329)2096 (13.09)
 TBLH BMD (g/cm2)0.91 (0.16)1.18 (0.08)
 LS BMC (g)30.76 (9.68)56.27 (1.17)
 LS BMD (g/cm2)0.71 (0.28)1.05 (0.06)
 LSBMAD (g/cm3)0.14 (0.04)0.18 (0.01)
 TBLH BMD-Ht (g/cm3)0.63 (0.08)0.75 (0.07)

PWS Prader: Willi syndrome, SDS standard deviation score, FM fat mass, FFM fat free mass, intelligence quotient (IQ) , BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone mineral density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.05 pediatric PWS with respect to pediatric controls

§p < 0.05 adult PWS with respect to adult controls

Fig. 1

Irisin levels in PWS subjects. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml) (a) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml) (b)

Figure image at the original source: open the original paper. This file is not included in this text import.
Fig. 2

Linking irisin levels to the genetic background and Vitamin D supplementation. Pediatric (a) and adult (b) PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively), but not UPD15. Adult PWS patients (c) without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02).

The lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001) (d)

Figure image at the original source: open the original paper. This file is not included in this text import.

We found that in the pediatric population only total cholesterol and LDL-C statistically differs between DEL15 and UPD15 (Table 2). About bone densitometric parameters, although there was a trend toward the reduction in UPD15 patients compared with DEL15 patients, this did not reach the statistical significance (Table 2). Interestingly, higher level of 25(OH) vitamin D were measured in UPD15 patients compared with DEL15 patients, but the difference did not achieve the statistical significance (Table 2).

Table 2

Clinical and biochemical characteristics of PWS patients according to genetic background

Pediatric DEL PWS, N = 16Pediatric UPD PWS, N = 10Adult DEL PWS, N = 38Adult UPD PWS, N = 14
Auxological parameters
 Gender (male/female)4/126/420/185/9
 Age (years)9.82 (5)10.71 (8.65)28.64 (22.00)21.59 (5.43)
 Height SDS− 0.66 (2.00)− 0.38 (2.60)Not reportedNot reported
 Weight SDS1.23 (2)1.22 (2.18)Not reportedNot reported
 BMI34.30 (15.00)32.34 (10.94)
 BMI-SDS1.92 (2)2.13 (3.82)Not reportedNot reported
 Total IQ71.00 (10.1)69.00 (3.6)58.17 (19.2)54.00 (10.00)
 Verbal IQNot reportedNot reported61.00 (18.75)57.00 (7.50)
 Performance IQNot reportedNot reported63.50 (19.25)68.00 (18.50)
Laboratory parameters
 Total cholesterol (mg/dl)148.0 (44)*174.5 (42.25)135.00 (28.00)158.0 (16.00)
 LDL-C (mg/dl)92 (34)*96.5 (32.25)70.00 (48.00)96.00 (12.00)
 HDL-C (mg/dl)54 (22)53.00 (24.50)47.00 (14.00)47.00 (17.00)
 Triglycerides (mg/dl)58 (41)83.00 (69.7)70.00 (36.00)67.00 (40.00)
 Glucose (mg/dl)77.50 (7.00)81.5 (16.5)85.00 (18.00)78.00 (39.00)
 Insulin (mU/l)9.17 (7.00)10.08 9.71)8.50 (5.55)10.51 (3.39)
 HOMA-index1.71 (1.00)2.06 (2.09)1.52 (0.67)1.60 (1.82)
 Osteocalcin (ng/ml)71.74 (26.42)91.00 (34.00)19.00 (16.00)12.0 (4.8)
 PTH (pg/ml)62 (36)35.00 (19.88)49.40 (23.6)26.00 (17.75)
 Ca (mg/dl)10 (1)9.55 0.37)9.30 (0.30)9.60 (0.36)
 P (mg/dl)4.80 (1)4.85 (1.15)3.60 (0.60)4.20 (0.41)
 25 (OH) vitamin D (ng/ml)22.60 (5.00)26.1 (4.65)31.60 (9.20)28.7 (10.5)
Bone parameters
 LBMD Z score0.69 (2.00)0.40 (1.00)Not reportedNot reported
 LS-BMD T scoreNot reportedNot reported− 1.00 (1.60)− 0.30 (1.02)
 TBLH BMC (g)1134 (299)1201 (225)2111 (274)2083 (93)
 TBLH BMD (g/cm2)0.83 (0.08)0.87 (0.11)1.10 (0.05)1.10 (0.05)
 LS BMC (g)31.85 (10.01)6.12 (5.51)59.49 (17.00)56.27 (9.43)
 LS BMD (g/cm2)0.71 (0.12)0.66 (0.10)0.99 (0.07)0.99 (0.07)
 LS BMAD (g/cm3)0.16 (0.02)0.13 (0.02)0.17 (0.009)0.67 (0.007)
 TBLHBMD-Ht0.63 (0.02)0.62 (0.13)0.67 (0.06)0.70 (0.06)

PWS Prader: Willi syndrome, SDS standard deviation score, IQ intelligence quotient, BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone minal density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.02 pediatric DEL PWS with respect to pediatric UPD PWS

Furthermore, we found that adult PWS patients performing vitamin D supplementation had irisin levels similar with controls, whereas adult PWS patients without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02, respectively), Fig. 2c. Consistently, adult PWS patients performing vitamin D supplementation showed significantly higher levels of 25(OH) vitamin D compared with PWS patients not performing the supplementation (33.39 ± 9.87 vs 27.03 ± 6.04, p < 0.05).

This issue was not investigated in pediatric PWS as only four performed vitamin D supplementation.

Finally, if we consider together the vitamin D supplementation and the genetics of adult PWS patients, the lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001, respectively) (Fig. 2d). Consistently, patients performing vitamin D supplementation showed high levels of circulating 25(OH) vitamin D compared with patients not performing the supplementation (DEL15 30.52 ± 9.17 vs 24.34 ± 5.60, p < 0.04; UPD15 36.98 ± 16.58 vs 30.62 ± 4.77, respectively).

Source: Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS Source: Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS Source: Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS Source: Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS

Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density

Results: Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density

Table 3 shows the correlations between irisin levels and anthropometric, metabolic parameters, cognitive performance and instrumental parameters of bone health in our study population. In pediatric PWS subjects the irisin levels positively correlated with BMI-SDS, weight-SDS, height-SDS, FM, FM%, glucose, insulin, HOMA-IR, vitamin D dosage supplementation, and 25(OH)-vitamin D levels; otherwise, the irisin levels negatively correlated with HDL, FFM%, calcium, and PTH. In PWS adults the irisin levels correlated positively with cholesterol, HDL, FM, FM%, years of GH therapy, glucose, age of sex steroid replacement therapy, age at start of GH therapy, LS-T-score, TBLH BMD-Ht, IQ, verbal IQ and performance IQ.

Otherwise, a negative correlation was found between irisin levels and 25(OH)-vitamin D levels, FFM%, calcium, and PTH.

Table 3

Significant correlations of irisin levels with anthropometric, metabolic, cognitive and instrumental parameters

Irisin (pediatric PWS)
BMI-SDSr = 0.562, p < 0.0001
Weight-SDSr = 0.682, p < 0.0001
Height-SDSr = 0.390, p < 0.0001
FM (g)r = 0.500, p < 0.0001
FM (%)r = 0.384, p < 0.001
FFM (%)r = − 0.384, p < 0.001
LS-BMD Z scorer = 0.137, p < 0.049
Glucoser = 0.282, p < 0.0001
Insulinr = 0.388, p < 0.0001
HOMA-IRr = 0.257, p < 0.0001
25(OH) vitamin Dr = 0.329, p < 0.0001
HDLr = − 0.313, p < 0.0001
Calciumr = − 0.177, p < 0.0001
PTHr = − 0.405, p < 0.0001
Irisin (adult PWS)
Cholesterolr = 0.266, p < 0.0001
LDLr = 0.220, p < 0.0001
HDLr = 0.416, p < 0.005
FM (g)r = 0.099, p < 0.001*
FM (%)r = 0.135, p < 0.0001*
FFM (%)r = − 0.083, p < 0.004*
25 (OH) vitamin Dr = − 0.103, p < 0.0001
Years of GH therapyr = 0.568, p < 0.02
Vitamin D supplementationr = − 0.383, p < 0.0001
LS BMD T scorer = 0.262, p < 0.0001
TBLH BMD-Htr = 0.064, p < 0.027
Glucoser = 0.205, p < 0.0001
Age of sex steroid replacement therapyr = 0.361, p < 0.0001
Age of GH therapyr = 0.328, p < 0.0001
Calciumr = − 0.084, p < 0.001
PTHr = − 0.203, p < 0.0001
IQr = 0.372, p < 0.04
Verbal IQr = 0.196, p < 0.0001
Performance IQr = 0.289, p < 0.0001

Additionally, multiple linear regression analyses were performed to explore the factors affecting irisin levels in PWS patients. Multiple linear regression analysis for irisin as dependent variable demonstrated that weight-SDS, genetics, 25(OH)-vitamin D levels and LS BMD Z score were the most important predictors in pediatric PWS subjects (Table 4). With adjustment for age, in adult PWS the best predictors for irisin levels were the genetic background, 25(OH)-vitamin D levels, GH therapy, the age at start and the duration of GH treatment, the age at start of sex steroid replacement therapy, IQ and TBLH BMD-Ht.

Table 4

Multiple regression analysis for pediatric and adult PWS

Dependent variableIndependent variableβpr
Model 1 (children)
0.00010.944
IrisinWeight-SDS0.2980.0001
Genetics−0.8020.0001
25 (OH) vitamin D0.0500.199
LS Z score0.1470.009
Model 2 (adults)
0.00010.665
IrisinGenetics−0.3820.0001
25 (OH) vitamin D0.3380.0001
GH therapy0.3700.0001
Age for GH therapy0.6940.0001
Age for sex steroid replacement treatment−0.1280.0001
Total BMD0.3780.0001
Model 3 (adults)
0.00010.750
IrisinGenetics−0.3650.0001
25 (OH) vitamin D0.3460.0001
GH Therapy−0.1390.0001
Age for GH Therapy0.3170.0001
Age for sex steroid replacement treatment−0.3240.0001
Total BMD0.4120.0001
Total IQ0.9100.0001
Source: Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density Source: Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density

Discussion

The present study displayed that PWS patients has comparable levels of irisin with respect to the controls; interestingly, a deepened analysis showed that both pediatric and adult PWS with DEL15 have significantly reduced levels of irisin compared with the controls, suggesting that the genetic background could be associated with a different metabolic profile in PWS [32]. Additionally, we also showed that patients who did not receive vitamin D supplementation had low serum levels of irisin, despite having the UPD as genetic alterations.

To our knowledge, this is the first study, which evaluated irisin levels both in PWS children and adults. Previous studies assessed irisin levels only in adult PWS patients. In detail, Hirsch et al. found higher levels of irisin in the saliva of PWS patients than controls, probably due to the different composition, and not significant differences in plasma levels between the two groups [17]. The same authors found that in PWS patients and controls plasma irisin levels positively correlated with total cholesterol and LDL, whereas in the saliva the myokine levels was inversely related with HDL, and directly with LDL and triglycerides [17].

Recently, the same research group again demonstrated that the serum levels of the myokine did not change in adult PWS compared with the controls, even if they performed a resistance exercise [18]. These results can be explained by the hypotonic muscle mass of these subjects.

Conversely, we found that irisin serum levels directly correlated with HDL in PWS children, whereas a positive correlation between irisin levels and total cholesterol, LDL, and HDL, but not with triglycerides was found in PWS adults. Recently, Mai et al. demonstrated that obese PWS adults showed comparable levels of irisin with respect to controls, but lower irisin amounts than obese subjects [19]. Interestingly, the authors also reported that in PWS patients irisin levels correlated with triglycerides [19].

This finding may be related to the peculiar body composition of PWS, characterized by lower visceral adipose tissue and decreased muscle mass [33], as well as to the impairment of adipose tissue observed in these subjects [34]. Consistently, we also found that irisin level correlated with FM and FFM. In agreement with our data, Mai et al. reported that a positive correlation was evident between irisin and FM% after adjustment for the PWS status [19].

On the other hand, our data showed that in the pediatric population the levels of the myokine correlated with BMI-SDS and weight-SDS, as well as parameters of glycemic and lipid metabolism.

Our paper is the first to demonstrate a direct correlation between the levels of this myokine and LS-BMD Z score and LS-BMD T score in pediatric and adult PWS, respectively. The anabolic role of irisin on bone has been demonstrated in healthy and osteoporotic mice [11, 12]. In humans, irisin correlates negatively with the serum levels of sclerostin, an inhibitor of Wnt β-catenin pathway [35]. Moreover, a direct correlation of the myokine with bone strength and BMD has been demonstrated in athletes [36] as well as in soccer players [37].

We also reported a positive association between bone status and serum irisin levels in healthy and diabetic children [38, 39]. In our population of pediatric and adult PWS subjects the irisin levels were negatively related to PTH. Consistently, in vitro experiments demonstrated a negative relationship between PTH and irisin, and these findings were further supported by the reduced concentration of the myokine in post-menopausal women with primary hyperparathyroidism with respect to the controls [40]. Although it has been reported that irisin levels were associated with osteoporotic fractures [41], in our study population previous post-traumatic fractures have been described only in five adult PWS patients, and thus it was not possible to evaluate the statistic relevance.

Interestingly, our study revealed that in pediatric PWS the vitamin D levels affected irisin serum concentration. This finding is a novelty in pediatric PWS population as previously we did not find significant correlation between irisin and 25(OH) vitamin D levels in healthy children [38]. The most of our pediatric PWS subjects showed normal vitamin D levels, thus they did not perform vitamin D supplementation, in contrast with our adult PWS population. Indeed, we demonstrated that irisin serum levels were reduced in adult patients without vitamin D supplementation, suggesting that vitamin D supplementation has an important role in regulating irisin levels in adult PWS patients.

Consistently, it has been recently reported that vitamin D supplementation improves irisin levels in obese type 2 diabetic patients [42].

In adult PWS patients we demonstrated a direct link with the age of sex steroid replacement therapy and the age of GH therapy, suggesting the key role of the beginning of the therapy to normalize the levels of the myokine in these subjects. Literature data reported the strict connection between irisin levels and GH as well as the favorable effect of GH replacement therapy on the myokine levels in children with GH deficiency [43].

Interestingly, irisin has been linked to cognitive impairment and neurodegenerative diseases [44], and in adults at risk of dementia its levels correlated with global cognition [45], thus irisin also could represent a serum biomarker of cognitive impairment. Although the results are referred only to 29 adult PWS, we showed that the levels of the myokine positively correlated with total IQ, verbal IQ and performance IQ. However, we did not find the same results for pediatric PWS, thus it is possible that it was evident only in adults, because the IQ impairment was more serious, but also maybe because we had total IQ evaluation only for a restricted number of pediatric subjects.

Consequently, this issue will require future investigations with larger study cohorts.

In conclusion, we did not find different irisin levels in PWS patients compared to matched controls, but we demonstrate possible role of genetic background in PWS on irisin level. Vitamin D supplementation may be key factor in regulating serum irisin levels.

Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion Source: Discussion

Results

Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS

Clinical and biochemical characteristics of PWS patients are reported in Table 1. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml, respectively) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml, respectively) (Fig. 1). A more in-depth analysis showed that the type of genetic alteration in PWS patients affected irisin levels. In fact, both pediatric and adult PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively) (Fig. 2a, b).

Otherwise, pediatric and adult PWS with UPD15 did not display significant differences compared with the controls (Fig. 2a, b). These findings prompted us to evaluate if there were significant differences among clinical, biochemical and bone parameters according to the genetic background.

Table 1

Clinical and biochemical characteristics of study population

Pediatric PWS, N = 26Pediatric controls, N = 26Adult PWS, N = 52Adult controls, N = 54
Auxological parameters
 Gender (male/female)11/159/1722/3028/26
 Age (years)10.86 (6)9.40 (3.29)36.00 (20.00)36.9 (18.5)
 Tanner (I/II/III/IV/V)23/1/2/0/022/2/2/0/00/0/25/25/20/0/0/0/54
 Height SDS− 0.70 (1.68)0.40 (1.21)Not reportedNot reported
 Weight SDS1.00 (1.95)0.53 (0.95)Not reportedNot reported
 BMI25.27 (8.4)23.4 (0.92)35.3 (12.1)§24.5 (2.1)
 BMI-SDS2.03 (1.76)0.30 (0.82)Not reportedNot reported
 FM (g)23,756 (8388)Not reported39,150 (16,311)Not reported
 FM (%)41.05 (12.7)Not reported50.50 (10.50)Not reported
 FFM (g)28,913 (9358)Not reported41,582 (10,181)Not reported
 FFM (%)55.93 (11.4)Not reported49.50 (9.00)Not reported
 Total IQ71.00 (20.00)Not reported57.00 (11.00)Not reported
 Verbal IQ-Not reported58.00 (11.00)Not reported
 Performance IQNot reportedNot reported66.00 (17.00)Not reported
Laboratory parameters
 Total cholesterol (mg/dl)159.9 (45.0)144.3 (18.6)180.0 (52.0)
 LDL: C (mg/dl)94.00 (27.0)78.1 (20.2)119.0 (42.0)
 HDL-C (mg/dl)54.00 (16.00)57.8 (8.6)48.0 (20.0)
 Triglycerides (mg/dl)64.00 (50.00)59.2 (15.4)95.0 (51.0)
 Glucose (mg/dl)78.00 ( 9.00)87.22 (11.35)90.0 (19.0)
 Insulin (mU/l)8.49 (6.71)9.2 (3.8)9.6 (5.51)
 HOMA-index1.61 (1.32)1.62 (0.8)2.15 (1.70)
 Osteocalcin (ng/ml)89.00 (14.35)*38.3 (19.2)19.00 (14.00)
 PTH (pg/ml)43.00 (34.00)19.25 ( 5.1)49.4 (34.3)
 Ca (mg/dl)9.80 (0.70)9.71 (0.40)9.50 (0.60)
 P (mg/dl)4.70 (0.80)4.54 (1.40)3.90 (0.70)
 25 (OH) vitamin D23.17 (6.70)28.8 (9.2)
Bone parameters
 LS-BMD Z score0.58 (1.51)Not reportedNot reported
 LS-BMD T score− 1.10 (0.20)Not reported
 TBLH BMC (g)1415 (329)2096 (13.09)
 TBLH BMD (g/cm2)0.91 (0.16)1.18 (0.08)
 LS BMC (g)30.76 (9.68)56.27 (1.17)
 LS BMD (g/cm2)0.71 (0.28)1.05 (0.06)
 LSBMAD (g/cm3)0.14 (0.04)0.18 (0.01)
 TBLH BMD-Ht (g/cm3)0.63 (0.08)0.75 (0.07)

PWS Prader: Willi syndrome, SDS standard deviation score, FM fat mass, FFM fat free mass, intelligence quotient (IQ) , BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone mineral density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.05 pediatric PWS with respect to pediatric controls

§p < 0.05 adult PWS with respect to adult controls

Fig. 1

Irisin levels in PWS subjects. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml) (a) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml) (b)

Figure image at the original source: open the original paper. This file is not included in this text import.
Fig. 2

Linking irisin levels to the genetic background and Vitamin D supplementation. Pediatric (a) and adult (b) PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively), but not UPD15. Adult PWS patients (c) without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02).

The lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001) (d)

Figure image at the original source: open the original paper. This file is not included in this text import.

We found that in the pediatric population only total cholesterol and LDL-C statistically differs between DEL15 and UPD15 (Table 2). About bone densitometric parameters, although there was a trend toward the reduction in UPD15 patients compared with DEL15 patients, this did not reach the statistical significance (Table 2). Interestingly, higher level of 25(OH) vitamin D were measured in UPD15 patients compared with DEL15 patients, but the difference did not achieve the statistical significance (Table 2).

Table 2

Clinical and biochemical characteristics of PWS patients according to genetic background

Pediatric DEL PWS, N = 16Pediatric UPD PWS, N = 10Adult DEL PWS, N = 38Adult UPD PWS, N = 14
Auxological parameters
 Gender (male/female)4/126/420/185/9
 Age (years)9.82 (5)10.71 (8.65)28.64 (22.00)21.59 (5.43)
 Height SDS− 0.66 (2.00)− 0.38 (2.60)Not reportedNot reported
 Weight SDS1.23 (2)1.22 (2.18)Not reportedNot reported
 BMI34.30 (15.00)32.34 (10.94)
 BMI-SDS1.92 (2)2.13 (3.82)Not reportedNot reported
 Total IQ71.00 (10.1)69.00 (3.6)58.17 (19.2)54.00 (10.00)
 Verbal IQNot reportedNot reported61.00 (18.75)57.00 (7.50)
 Performance IQNot reportedNot reported63.50 (19.25)68.00 (18.50)
Laboratory parameters
 Total cholesterol (mg/dl)148.0 (44)*174.5 (42.25)135.00 (28.00)158.0 (16.00)
 LDL-C (mg/dl)92 (34)*96.5 (32.25)70.00 (48.00)96.00 (12.00)
 HDL-C (mg/dl)54 (22)53.00 (24.50)47.00 (14.00)47.00 (17.00)
 Triglycerides (mg/dl)58 (41)83.00 (69.7)70.00 (36.00)67.00 (40.00)
 Glucose (mg/dl)77.50 (7.00)81.5 (16.5)85.00 (18.00)78.00 (39.00)
 Insulin (mU/l)9.17 (7.00)10.08 9.71)8.50 (5.55)10.51 (3.39)
 HOMA-index1.71 (1.00)2.06 (2.09)1.52 (0.67)1.60 (1.82)
 Osteocalcin (ng/ml)71.74 (26.42)91.00 (34.00)19.00 (16.00)12.0 (4.8)
 PTH (pg/ml)62 (36)35.00 (19.88)49.40 (23.6)26.00 (17.75)
 Ca (mg/dl)10 (1)9.55 0.37)9.30 (0.30)9.60 (0.36)
 P (mg/dl)4.80 (1)4.85 (1.15)3.60 (0.60)4.20 (0.41)
 25 (OH) vitamin D (ng/ml)22.60 (5.00)26.1 (4.65)31.60 (9.20)28.7 (10.5)
Bone parameters
 LBMD Z score0.69 (2.00)0.40 (1.00)Not reportedNot reported
 LS-BMD T scoreNot reportedNot reported− 1.00 (1.60)− 0.30 (1.02)
 TBLH BMC (g)1134 (299)1201 (225)2111 (274)2083 (93)
 TBLH BMD (g/cm2)0.83 (0.08)0.87 (0.11)1.10 (0.05)1.10 (0.05)
 LS BMC (g)31.85 (10.01)6.12 (5.51)59.49 (17.00)56.27 (9.43)
 LS BMD (g/cm2)0.71 (0.12)0.66 (0.10)0.99 (0.07)0.99 (0.07)
 LS BMAD (g/cm3)0.16 (0.02)0.13 (0.02)0.17 (0.009)0.67 (0.007)
 TBLHBMD-Ht0.63 (0.02)0.62 (0.13)0.67 (0.06)0.70 (0.06)

PWS Prader: Willi syndrome, SDS standard deviation score, IQ intelligence quotient, BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone minal density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.02 pediatric DEL PWS with respect to pediatric UPD PWS

Furthermore, we found that adult PWS patients performing vitamin D supplementation had irisin levels similar with controls, whereas adult PWS patients without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02, respectively), Fig. 2c. Consistently, adult PWS patients performing vitamin D supplementation showed significantly higher levels of 25(OH) vitamin D compared with PWS patients not performing the supplementation (33.39 ± 9.87 vs 27.03 ± 6.04, p < 0.05).

This issue was not investigated in pediatric PWS as only four performed vitamin D supplementation.

Finally, if we consider together the vitamin D supplementation and the genetics of adult PWS patients, the lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001, respectively) (Fig. 2d). Consistently, patients performing vitamin D supplementation showed high levels of circulating 25(OH) vitamin D compared with patients not performing the supplementation (DEL15 30.52 ± 9.17 vs 24.34 ± 5.60, p < 0.04; UPD15 36.98 ± 16.58 vs 30.62 ± 4.77, respectively).

Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density

Table 3 shows the correlations between irisin levels and anthropometric, metabolic parameters, cognitive performance and instrumental parameters of bone health in our study population. In pediatric PWS subjects the irisin levels positively correlated with BMI-SDS, weight-SDS, height-SDS, FM, FM%, glucose, insulin, HOMA-IR, vitamin D dosage supplementation, and 25(OH)-vitamin D levels; otherwise, the irisin levels negatively correlated with HDL, FFM%, calcium, and PTH. In PWS adults the irisin levels correlated positively with cholesterol, HDL, FM, FM%, years of GH therapy, glucose, age of sex steroid replacement therapy, age at start of GH therapy, LS-T-score, TBLH BMD-Ht, IQ, verbal IQ and performance IQ.

Otherwise, a negative correlation was found between irisin levels and 25(OH)-vitamin D levels, FFM%, calcium, and PTH.

Table 3

Significant correlations of irisin levels with anthropometric, metabolic, cognitive and instrumental parameters

Irisin (pediatric PWS)
BMI-SDSr = 0.562, p < 0.0001
Weight-SDSr = 0.682, p < 0.0001
Height-SDSr = 0.390, p < 0.0001
FM (g)r = 0.500, p < 0.0001
FM (%)r = 0.384, p < 0.001
FFM (%)r = − 0.384, p < 0.001
LS-BMD Z scorer = 0.137, p < 0.049
Glucoser = 0.282, p < 0.0001
Insulinr = 0.388, p < 0.0001
HOMA-IRr = 0.257, p < 0.0001
25(OH) vitamin Dr = 0.329, p < 0.0001
HDLr = − 0.313, p < 0.0001
Calciumr = − 0.177, p < 0.0001
PTHr = − 0.405, p < 0.0001
Irisin (adult PWS)
Cholesterolr = 0.266, p < 0.0001
LDLr = 0.220, p < 0.0001
HDLr = 0.416, p < 0.005
FM (g)r = 0.099, p < 0.001*
FM (%)r = 0.135, p < 0.0001*
FFM (%)r = − 0.083, p < 0.004*
25 (OH) vitamin Dr = − 0.103, p < 0.0001
Years of GH therapyr = 0.568, p < 0.02
Vitamin D supplementationr = − 0.383, p < 0.0001
LS BMD T scorer = 0.262, p < 0.0001
TBLH BMD-Htr = 0.064, p < 0.027
Glucoser = 0.205, p < 0.0001
Age of sex steroid replacement therapyr = 0.361, p < 0.0001
Age of GH therapyr = 0.328, p < 0.0001
Calciumr = − 0.084, p < 0.001
PTHr = − 0.203, p < 0.0001
IQr = 0.372, p < 0.04
Verbal IQr = 0.196, p < 0.0001
Performance IQr = 0.289, p < 0.0001

Additionally, multiple linear regression analyses were performed to explore the factors affecting irisin levels in PWS patients. Multiple linear regression analysis for irisin as dependent variable demonstrated that weight-SDS, genetics, 25(OH)-vitamin D levels and LS BMD Z score were the most important predictors in pediatric PWS subjects (Table 4). With adjustment for age, in adult PWS the best predictors for irisin levels were the genetic background, 25(OH)-vitamin D levels, GH therapy, the age at start and the duration of GH treatment, the age at start of sex steroid replacement therapy, IQ and TBLH BMD-Ht.

Table 4

Multiple regression analysis for pediatric and adult PWS

Dependent variableIndependent variableβpr
Model 1 (children)
0.00010.944
IrisinWeight-SDS0.2980.0001
Genetics−0.8020.0001
25 (OH) vitamin D0.0500.199
LS Z score0.1470.009
Model 2 (adults)
0.00010.665
IrisinGenetics−0.3820.0001
25 (OH) vitamin D0.3380.0001
GH therapy0.3700.0001
Age for GH therapy0.6940.0001
Age for sex steroid replacement treatment−0.1280.0001
Total BMD0.3780.0001
Model 3 (adults)
0.00010.750
IrisinGenetics−0.3650.0001
25 (OH) vitamin D0.3460.0001
GH Therapy−0.1390.0001
Age for GH Therapy0.3170.0001
Age for sex steroid replacement treatment−0.3240.0001
Total BMD0.4120.0001
Total IQ0.9100.0001
Source: Results Source: Results

Abstract: Conclusion

We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.

Source: Conclusion
Authors’ abstract

Background

Prader: Willi syndrome (PWS) is associated to distinctive clinical symptoms, including obesity, cognitive and behavioral disorders, and bone impairment. Irisin is a myokine that acts on several target organs including brain adipose tissue and bone. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients.

Methods

Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were enrolled. Irisin serum levels were measured in patients and controls. Its levels were related with anthropometric and metabolic parameters, cognitive performance and bone mineral density either in pediatric or adult PWS. Multiple regression analysis was also performed.

Results

Irisin serum levels in PWS patients did not show different compared with controls. A more in-depth analysis showed that both pediatric and adult PWS with DEL15 displayed significantly reduced irisin levels compared to controls. Otherwise, no differences in irisin concentration were found in UPD15 patients with respect to controls. Our study revealed that in pediatric PWS the 25(OH) vitamin-D levels affected irisin serum concentration. Indeed, patients who were not supplemented with vitamin D showed lower irisin levels than controls and patients performing the supplementation.

Multiple regression analysis showed that irisin levels in pediatric and adult PWS were predicted by the genetic background and 25(OH)-vitamin D levels, whereas in a group of 29 adult PWS also by intelligent quotient.

Conclusion

We demonstrated the possible role of genetic background and vitamin-D supplementation on irisin serum levels in PWS patients.

Read the full paper

Introduction

Prader: Willi syndrome (PWS) is a rare genetic disease with distinctive clinical symptoms that critically impair patients’ quality of life. PWS arises because of the lack of expression of genes located on the paternal chromosome 15q11.2: q13. Three main genetic mechanisms have been recognized in determining PWS: interstitial deletion of the proximal long arm of chromosome 15 (del15q11: q13) (DEL15), maternal uniparental disomy of chromosome 15 (UPD15), and imprinting defects [1]. The main features of the PWS phenotype are broader, and include neonatal hypotonia, poor feeding and initial failure to thrive, followed by hyperphagia and early childhood-onset obesity (if uncontrolled), multiple endocrine abnormalities (including growth hormone deficiency (GHD) and hypogonadism], motor development problems, dysmorphic features, cognitive impairment, and behavioral issues [2]).

Notably, PWS patients also show bone impairment. In detail, prepubertal PWS children display normal bone mineral density (BMD) (if adjusted for the reduced height) [3Not reported5], but in adolescence and adulthood, they presented decreased total BMD and bone mineral content (BMC) possible, because they did not achieve bone mineral accrual, also due to pubertal delay/hypogonadism [6Not reported9]. Consequently, osteoporosis is predominant in PWS individuals, who also have other orthopedic complications related or worsened by weight gain, including scoliosis, kyphosis, hip dysplasia, flat feet, genu valgum and fractures [8, 10].

Recently, researchers have shown an increased interest on irisin, a myokine primarily secreted by skeletal muscle, involved in bone, adipose tissue and brain homeostasis. In detail, in young mice irisin injection mimicked the effects of exercise by increasing cortical bone mass and strength [11]. In hindlimb unloaded mice, intermittent administration of irisin prevented bone loss [12]. Interestingly, the myokine is also known to determine the browning of white adipose tissue [13] and to work as an adipokine as it is secreted by the same tissue [14].

Additionally, it has also been reported that irisin may have an effect on certain brain functions, and consequently it is involved in cognitive impairment and in neurodegenerative disease [15, 16]. These issues prompted some authors to evaluate irisin levels in adult PWS patients. In detail, Hirsch et al. found increased amounts of salivary irisin in obese PWS with respect to non-obese controls, whereas the plasma levels of irisin did not change significantly between the two groups [17, 18].

Recently, Mai et al. also reported that PWS patients and controls have similar circulating irisin levels [19]. The present study was finalized to explore circulating levels of irisin in children and adult PWS patients in relation to the genetic background, metabolic profile, cognitive impairment and bone status.

Materials and methods

Patients

Seventy-eight subjects with PWS, 26 children (15 females, mean age 9.48 ± 3.6 years) and 52 adults (30 females, mean age 30.6 ± 10.7) were included in this study. All patients showed the typical PWS clinical phenotype [20]. Genetic investigation was performed in all PWS patients, and 48 of them had DEL15 (32 adults and 16 children), while UPD15 was found in the remaining individuals (20 adults and 10 children).

All PWS children were on growth hormone (GH) treatment from at least 12 months, at a dosage ranging from 0.025 to 0.035 mg/kg/day. Among PWS adults, 6 out of the 52 subjects presented a severe degree of GHD, according to a GH response to GHRH plus arginine less than 4.2 ng/ml [21], and received GH therapy at a mean dose of 0.23 mg/day. At all ages, the GH dose was adjusted to maintain serum total IGF-I within 2 SD from an age-matched reference value to avoid overdosing.

At the time of the study, 10 females and 1 male underwent sex steroid replacement treatment.

As controls, we evaluated a group of 26 children (17 females, mean age 9.4 ± 3.29 years), referred to our hospital for minor surgery or electrocardiographic screening, and 54 normal weight adults (26 females, mean age 36.5 ± 12.5 years) enrolled on a voluntary basis.

PWS and control children performed an average of 2 h per week of school sports, whereas adult PWS and controls about 3 h per week. Four out of 26 PWS children (15%) and 26 out of 52 PWS adults (50%) were on vitamin D supplementation at the moment of the study [cholecalciferol mean dosage: children 500 UI/daily (12.5 mcg/daily); adults 800 UI/daily (20 mcg/daily)].

Exclusion criteria from the study for both patients and controls were the use of mineral and vitamin supplements, except for vitamin D, the presence of chronic diseases with a possible impact on bone metabolism (e.g., hypothyroidism or hyperthyroidism, Cushing’s syndrome, celiac disease, anorexia nervosa, etc.), the use of medications affecting bone turnover, e.g., corticosteroids, and fractures in 6 months preceding the study. Five adult PWS patients had a history of previous post-traumatic fractures at different sites (ankle, ulna, radio, malleolus, fibula, and phalanges).

None of the PWS pediatric patients experienced fractures.

No patient had previously undergone bariatric surgery.

Written informed consent was obtained from all the legal guardians, and from the patients when applicable, prior to inclusion. All procedures were approved by local institutional review boards.

Anthropometric measurements

All patients underwent a general clinical examination, anthropometric measurements (height in cm, weight in kg) and, for the pediatric age, data were plotted on Italian growth charts and computed as percentiles and SDS [22]. BMI was defined as weight in kilograms divided by the square of height in meters. The international standards for sex: and age-specific BMI percentiles were used for subjects aged 2 to 18 years [22]. BMI standard deviation score (SDS) was derived from the published Center for Disease Control and Prevention (CDC) standards [23].

The BMI cut-off point of > 2 SDS was used to define obesity, and between 1.4 and 2 SDS to define overweight for individuals < 18 years of age. Considering adult age, we considered as obese, overweight and normal-weight those subjects with a BMI > 30, in the range of 25 to 30 and < 25, respectively (NIH). The pubertal and genital stages were assessed according to the Tanner criteria [24].

Biochemical measurements

Blood samples were drawn under fasting conditions, centrifuged, and stored at − 80 °C until required. Blood glucose, insulin, total cholesterol (TC), high (HDL) and low (LDL) density lipoprotein cholesterol, triglycerides (TG), were measured after overnight fasting in all subjects, using standard methods. Values of TC, LDL, HDL, and TG were considered in the normal range if within the 5th and the 95th percentile. Calcium, phosphorus and alkaline phosphatase (ALP) concentrations were measured by the nephelometric method. Serum active intact parathyroid hormone (PTH) and 25(OH) vitamin D were measured by immunological tests based on the principle of chemiluminescence using commercial kits (Liaison assay; DiaSorin, Stillwater, Minnesota, USA).

Osteocalcin serum concentration was measured by enzyme immunoassay (IBL International GmbH, Hamburg, Germany). Irisin levels were assessed using a commercially available kit (AdipoGen, Liestal, Switzerland). Insulin resistance was assessed calculating the homeostasis model assessment (HOMA) [25].

Dual-energy X-ray absorptiometry (DXA)

Bone mass of the anterior: posterior lumbar spine (L1: 4) and the total body (TB) was measured by DXA using a Hologic QDR Discovery, and the APEX-system software version 13.3 (Hologic Bedford, MA) with fan beam in array mode. The measurements were performed using standard positioning techniques. Quality control scans were performed daily using a simulated L1: 4 lumbar spine phantom. The lumbar spine DXA scan were analyzed to generate measures of L1: L4 vertebral areal BMD (LSBMD, g/cm2), bone mineral content (LSBMC, g), spine volumetric BMD (LSBMAD, g/cm3) lumbar spine Z score (LSBMD Z score, SDS) [26Not reported28].

Total body scans were obtained to estimate fat mass (FM%), fat free mass (FFM%) expressed as percentage of total body weight (bone mass with the skull excluded from analysis (total body less head, TBLH). Bone variables included BMD (TBLH BMD, g/cm2), BMC (TBLH BMC, g); BMD were normalized for height (TBLH BMD-Ht, g/cm3) to avoid any influence of growth on bone mass [28].

IQ assessment

Global IQ evaluation was assessed in a subgroup of patients based on age. In details, in pediatric PWS it was used Wechsler Intelligence Scale for Children-IV (WISC-IV, n = 6) [29] or Leiter International Performance Scale (n = 5) [30]. The Wechsler Adult Intelligence Scale-IV (WAIS-IV) was used in 29 PWS adults. This test allowed the calculation of the total intelligence quotient (IQ) through the standardized administration of scales, including verbal subtests to determine the verbal quotient (VQ), and performance subtests to determine performance quotient (PQ) [31].

Statistical analyses

Results are shown as median with interquartiles. The Kolmogorov: Smirnov test was utilized to assess the normality of parameter distribution. Mean values were compared by the unpaired Student t-test in parameters with normal distribution, and linear correlations evaluated with Pearson’s correlation coefficient. Significance was calculated with the Mann: Whitney test and Spearman’s correlation coefficient in parameters with skewed distribution. Multiple regression analyses were applied to identify the relative strength of each biochemical and clinical variable in predicting irisin levels. The Statistical Package for the Social Sciences (SPSS) for Windows, version 22.0 (SPSS Inc., Chicago, IL, USA) was utilized for statistical analysis.

The limit of statistical significance was set at 0.05.

Results

Linking irisin levels to the genetic background and metabolic profile and bone health in pediatric and adult PWS

Clinical and biochemical characteristics of PWS patients are reported in Table 1. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml, respectively) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml, respectively) (Fig. 1). A more in-depth analysis showed that the type of genetic alteration in PWS patients affected irisin levels. In fact, both pediatric and adult PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively) (Fig. 2a, b).

Otherwise, pediatric and adult PWS with UPD15 did not display significant differences compared with the controls (Fig. 2a, b). These findings prompted us to evaluate if there were significant differences among clinical, biochemical and bone parameters according to the genetic background.

Table 1

Clinical and biochemical characteristics of study population

Pediatric PWS, N = 26Pediatric controls, N = 26Adult PWS, N = 52Adult controls, N = 54
Auxological parameters
 Gender (male/female)11/159/1722/3028/26
 Age (years)10.86 (6)9.40 (3.29)36.00 (20.00)36.9 (18.5)
 Tanner (I/II/III/IV/V)23/1/2/0/022/2/2/0/00/0/25/25/20/0/0/0/54
 Height SDS− 0.70 (1.68)0.40 (1.21)Not reportedNot reported
 Weight SDS1.00 (1.95)0.53 (0.95)Not reportedNot reported
 BMI25.27 (8.4)23.4 (0.92)35.3 (12.1)§24.5 (2.1)
 BMI-SDS2.03 (1.76)0.30 (0.82)Not reportedNot reported
 FM (g)23,756 (8388)Not reported39,150 (16,311)Not reported
 FM (%)41.05 (12.7)Not reported50.50 (10.50)Not reported
 FFM (g)28,913 (9358)Not reported41,582 (10,181)Not reported
 FFM (%)55.93 (11.4)Not reported49.50 (9.00)Not reported
 Total IQ71.00 (20.00)Not reported57.00 (11.00)Not reported
 Verbal IQ-Not reported58.00 (11.00)Not reported
 Performance IQNot reportedNot reported66.00 (17.00)Not reported
Laboratory parameters
 Total cholesterol (mg/dl)159.9 (45.0)144.3 (18.6)180.0 (52.0)
 LDL: C (mg/dl)94.00 (27.0)78.1 (20.2)119.0 (42.0)
 HDL-C (mg/dl)54.00 (16.00)57.8 (8.6)48.0 (20.0)
 Triglycerides (mg/dl)64.00 (50.00)59.2 (15.4)95.0 (51.0)
 Glucose (mg/dl)78.00 ( 9.00)87.22 (11.35)90.0 (19.0)
 Insulin (mU/l)8.49 (6.71)9.2 (3.8)9.6 (5.51)
 HOMA-index1.61 (1.32)1.62 (0.8)2.15 (1.70)
 Osteocalcin (ng/ml)89.00 (14.35)*38.3 (19.2)19.00 (14.00)
 PTH (pg/ml)43.00 (34.00)19.25 ( 5.1)49.4 (34.3)
 Ca (mg/dl)9.80 (0.70)9.71 (0.40)9.50 (0.60)
 P (mg/dl)4.70 (0.80)4.54 (1.40)3.90 (0.70)
 25 (OH) vitamin D23.17 (6.70)28.8 (9.2)
Bone parameters
 LS-BMD Z score0.58 (1.51)Not reportedNot reported
 LS-BMD T score− 1.10 (0.20)Not reported
 TBLH BMC (g)1415 (329)2096 (13.09)
 TBLH BMD (g/cm2)0.91 (0.16)1.18 (0.08)
 LS BMC (g)30.76 (9.68)56.27 (1.17)
 LS BMD (g/cm2)0.71 (0.28)1.05 (0.06)
 LSBMAD (g/cm3)0.14 (0.04)0.18 (0.01)
 TBLH BMD-Ht (g/cm3)0.63 (0.08)0.75 (0.07)

PWS Prader: Willi syndrome, SDS standard deviation score, FM fat mass, FFM fat free mass, intelligence quotient (IQ) , BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone mineral density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.05 pediatric PWS with respect to pediatric controls

§p < 0.05 adult PWS with respect to adult controls

Fig. 1

Irisin levels in PWS subjects. Mean serum irisin levels did not change significantly between PWS children and controls (4.37 ± 2.30 μg/ml vs 5.31 ± 2.13 μg/ml) (a) as well as between adult PWS and controls (6.65 ± 4.49 μg/ml vs 7.24 ± 5.20 μg/ml) (b)

Figure image at the original source: open the original paper. This file is not included in this text import.
Fig. 2

Linking irisin levels to the genetic background and Vitamin D supplementation. Pediatric (a) and adult (b) PWS with DEL15 showed significantly reduced irisin levels compared with the controls (p < 0.02 and p < 0.04, respectively), but not UPD15. Adult PWS patients (c) without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02).

The lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001) (d)

Figure image at the original source: open the original paper. This file is not included in this text import.

We found that in the pediatric population only total cholesterol and LDL-C statistically differs between DEL15 and UPD15 (Table 2). About bone densitometric parameters, although there was a trend toward the reduction in UPD15 patients compared with DEL15 patients, this did not reach the statistical significance (Table 2). Interestingly, higher level of 25(OH) vitamin D were measured in UPD15 patients compared with DEL15 patients, but the difference did not achieve the statistical significance (Table 2).

Table 2

Clinical and biochemical characteristics of PWS patients according to genetic background

Pediatric DEL PWS, N = 16Pediatric UPD PWS, N = 10Adult DEL PWS, N = 38Adult UPD PWS, N = 14
Auxological parameters
 Gender (male/female)4/126/420/185/9
 Age (years)9.82 (5)10.71 (8.65)28.64 (22.00)21.59 (5.43)
 Height SDS− 0.66 (2.00)− 0.38 (2.60)Not reportedNot reported
 Weight SDS1.23 (2)1.22 (2.18)Not reportedNot reported
 BMI34.30 (15.00)32.34 (10.94)
 BMI-SDS1.92 (2)2.13 (3.82)Not reportedNot reported
 Total IQ71.00 (10.1)69.00 (3.6)58.17 (19.2)54.00 (10.00)
 Verbal IQNot reportedNot reported61.00 (18.75)57.00 (7.50)
 Performance IQNot reportedNot reported63.50 (19.25)68.00 (18.50)
Laboratory parameters
 Total cholesterol (mg/dl)148.0 (44)*174.5 (42.25)135.00 (28.00)158.0 (16.00)
 LDL-C (mg/dl)92 (34)*96.5 (32.25)70.00 (48.00)96.00 (12.00)
 HDL-C (mg/dl)54 (22)53.00 (24.50)47.00 (14.00)47.00 (17.00)
 Triglycerides (mg/dl)58 (41)83.00 (69.7)70.00 (36.00)67.00 (40.00)
 Glucose (mg/dl)77.50 (7.00)81.5 (16.5)85.00 (18.00)78.00 (39.00)
 Insulin (mU/l)9.17 (7.00)10.08 9.71)8.50 (5.55)10.51 (3.39)
 HOMA-index1.71 (1.00)2.06 (2.09)1.52 (0.67)1.60 (1.82)
 Osteocalcin (ng/ml)71.74 (26.42)91.00 (34.00)19.00 (16.00)12.0 (4.8)
 PTH (pg/ml)62 (36)35.00 (19.88)49.40 (23.6)26.00 (17.75)
 Ca (mg/dl)10 (1)9.55 0.37)9.30 (0.30)9.60 (0.36)
 P (mg/dl)4.80 (1)4.85 (1.15)3.60 (0.60)4.20 (0.41)
 25 (OH) vitamin D (ng/ml)22.60 (5.00)26.1 (4.65)31.60 (9.20)28.7 (10.5)
Bone parameters
 LBMD Z score0.69 (2.00)0.40 (1.00)Not reportedNot reported
 LS-BMD T scoreNot reportedNot reported− 1.00 (1.60)− 0.30 (1.02)
 TBLH BMC (g)1134 (299)1201 (225)2111 (274)2083 (93)
 TBLH BMD (g/cm2)0.83 (0.08)0.87 (0.11)1.10 (0.05)1.10 (0.05)
 LS BMC (g)31.85 (10.01)6.12 (5.51)59.49 (17.00)56.27 (9.43)
 LS BMD (g/cm2)0.71 (0.12)0.66 (0.10)0.99 (0.07)0.99 (0.07)
 LS BMAD (g/cm3)0.16 (0.02)0.13 (0.02)0.17 (0.009)0.67 (0.007)
 TBLHBMD-Ht0.63 (0.02)0.62 (0.13)0.67 (0.06)0.70 (0.06)

PWS Prader: Willi syndrome, SDS standard deviation score, IQ intelligence quotient, BMI body mass index, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, HOMA index homeostasis model assessment index, PTH parathyroid hormone, Ca calcium, P phosphorus, LS lumbar spine, TBLH total body less head, BMD bone minal density, BMAD bone mineral apparent density, BMD-Ht height adjusted

*p < 0.02 pediatric DEL PWS with respect to pediatric UPD PWS

Furthermore, we found that adult PWS patients performing vitamin D supplementation had irisin levels similar with controls, whereas adult PWS patients without vitamin D supplementation showed a significant reduction of the myokine levels compared with the controls and the patients performing the supplementation (p < 0.001 and p < 0.02, respectively), Fig. 2c. Consistently, adult PWS patients performing vitamin D supplementation showed significantly higher levels of 25(OH) vitamin D compared with PWS patients not performing the supplementation (33.39 ± 9.87 vs 27.03 ± 6.04, p < 0.05).

This issue was not investigated in pediatric PWS as only four performed vitamin D supplementation.

Finally, if we consider together the vitamin D supplementation and the genetics of adult PWS patients, the lowest levels of irisin are associated to the lacking of vitamin D supplementation for both DEL15 and UPD15 groups (p < 0.004 and p < 0.001, respectively) (Fig. 2d). Consistently, patients performing vitamin D supplementation showed high levels of circulating 25(OH) vitamin D compared with patients not performing the supplementation (DEL15 30.52 ± 9.17 vs 24.34 ± 5.60, p < 0.04; UPD15 36.98 ± 16.58 vs 30.62 ± 4.77, respectively).

Correlations and multiple regression analysis among irisin levels and anthropometric and metabolic parameters as well as cognitive performance and bone mineral density

Table 3 shows the correlations between irisin levels and anthropometric, metabolic parameters, cognitive performance and instrumental parameters of bone health in our study population. In pediatric PWS subjects the irisin levels positively correlated with BMI-SDS, weight-SDS, height-SDS, FM, FM%, glucose, insulin, HOMA-IR, vitamin D dosage supplementation, and 25(OH)-vitamin D levels; otherwise, the irisin levels negatively correlated with HDL, FFM%, calcium, and PTH. In PWS adults the irisin levels correlated positively with cholesterol, HDL, FM, FM%, years of GH therapy, glucose, age of sex steroid replacement therapy, age at start of GH therapy, LS-T-score, TBLH BMD-Ht, IQ, verbal IQ and performance IQ.

Otherwise, a negative correlation was found between irisin levels and 25(OH)-vitamin D levels, FFM%, calcium, and PTH.

Table 3

Significant correlations of irisin levels with anthropometric, metabolic, cognitive and instrumental parameters

Irisin (pediatric PWS)
BMI-SDSr = 0.562, p < 0.0001
Weight-SDSr = 0.682, p < 0.0001
Height-SDSr = 0.390, p < 0.0001
FM (g)r = 0.500, p < 0.0001
FM (%)r = 0.384, p < 0.001
FFM (%)r = − 0.384, p < 0.001
LS-BMD Z scorer = 0.137, p < 0.049
Glucoser = 0.282, p < 0.0001
Insulinr = 0.388, p < 0.0001
HOMA-IRr = 0.257, p < 0.0001
25(OH) vitamin Dr = 0.329, p < 0.0001
HDLr = − 0.313, p < 0.0001
Calciumr = − 0.177, p < 0.0001
PTHr = − 0.405, p < 0.0001
Irisin (adult PWS)
Cholesterolr = 0.266, p < 0.0001
LDLr = 0.220, p < 0.0001
HDLr = 0.416, p < 0.005
FM (g)r = 0.099, p < 0.001*
FM (%)r = 0.135, p < 0.0001*
FFM (%)r = − 0.083, p < 0.004*
25 (OH) vitamin Dr = − 0.103, p < 0.0001
Years of GH therapyr = 0.568, p < 0.02
Vitamin D supplementationr = − 0.383, p < 0.0001
LS BMD T scorer = 0.262, p < 0.0001
TBLH BMD-Htr = 0.064, p < 0.027
Glucoser = 0.205, p < 0.0001
Age of sex steroid replacement therapyr = 0.361, p < 0.0001
Age of GH therapyr = 0.328, p < 0.0001
Calciumr = − 0.084, p < 0.001
PTHr = − 0.203, p < 0.0001
IQr = 0.372, p < 0.04
Verbal IQr = 0.196, p < 0.0001
Performance IQr = 0.289, p < 0.0001

Additionally, multiple linear regression analyses were performed to explore the factors affecting irisin levels in PWS patients. Multiple linear regression analysis for irisin as dependent variable demonstrated that weight-SDS, genetics, 25(OH)-vitamin D levels and LS BMD Z score were the most important predictors in pediatric PWS subjects (Table 4). With adjustment for age, in adult PWS the best predictors for irisin levels were the genetic background, 25(OH)-vitamin D levels, GH therapy, the age at start and the duration of GH treatment, the age at start of sex steroid replacement therapy, IQ and TBLH BMD-Ht.

Table 4

Multiple regression analysis for pediatric and adult PWS

Dependent variableIndependent variableβpr
Model 1 (children)
0.00010.944
IrisinWeight-SDS0.2980.0001
Genetics−0.8020.0001
25 (OH) vitamin D0.0500.199
LS Z score0.1470.009
Model 2 (adults)
0.00010.665
IrisinGenetics−0.3820.0001
25 (OH) vitamin D0.3380.0001
GH therapy0.3700.0001
Age for GH therapy0.6940.0001
Age for sex steroid replacement treatment−0.1280.0001
Total BMD0.3780.0001
Model 3 (adults)
0.00010.750
IrisinGenetics−0.3650.0001
25 (OH) vitamin D0.3460.0001
GH Therapy−0.1390.0001
Age for GH Therapy0.3170.0001
Age for sex steroid replacement treatment−0.3240.0001
Total BMD0.4120.0001
Total IQ0.9100.0001

Discussion

The present study displayed that PWS patients has comparable levels of irisin with respect to the controls; interestingly, a deepened analysis showed that both pediatric and adult PWS with DEL15 have significantly reduced levels of irisin compared with the controls, suggesting that the genetic background could be associated with a different metabolic profile in PWS [32]. Additionally, we also showed that patients who did not receive vitamin D supplementation had low serum levels of irisin, despite having the UPD as genetic alterations.

To our knowledge, this is the first study, which evaluated irisin levels both in PWS children and adults. Previous studies assessed irisin levels only in adult PWS patients. In detail, Hirsch et al. found higher levels of irisin in the saliva of PWS patients than controls, probably due to the different composition, and not significant differences in plasma levels between the two groups [17]. The same authors found that in PWS patients and controls plasma irisin levels positively correlated with total cholesterol and LDL, whereas in the saliva the myokine levels was inversely related with HDL, and directly with LDL and triglycerides [17].

Recently, the same research group again demonstrated that the serum levels of the myokine did not change in adult PWS compared with the controls, even if they performed a resistance exercise [18]. These results can be explained by the hypotonic muscle mass of these subjects.

Conversely, we found that irisin serum levels directly correlated with HDL in PWS children, whereas a positive correlation between irisin levels and total cholesterol, LDL, and HDL, but not with triglycerides was found in PWS adults. Recently, Mai et al. demonstrated that obese PWS adults showed comparable levels of irisin with respect to controls, but lower irisin amounts than obese subjects [19]. Interestingly, the authors also reported that in PWS patients irisin levels correlated with triglycerides [19].

This finding may be related to the peculiar body composition of PWS, characterized by lower visceral adipose tissue and decreased muscle mass [33], as well as to the impairment of adipose tissue observed in these subjects [34]. Consistently, we also found that irisin level correlated with FM and FFM. In agreement with our data, Mai et al. reported that a positive correlation was evident between irisin and FM% after adjustment for the PWS status [19].

On the other hand, our data showed that in the pediatric population the levels of the myokine correlated with BMI-SDS and weight-SDS, as well as parameters of glycemic and lipid metabolism.

Our paper is the first to demonstrate a direct correlation between the levels of this myokine and LS-BMD Z score and LS-BMD T score in pediatric and adult PWS, respectively. The anabolic role of irisin on bone has been demonstrated in healthy and osteoporotic mice [11, 12]. In humans, irisin correlates negatively with the serum levels of sclerostin, an inhibitor of Wnt β-catenin pathway [35]. Moreover, a direct correlation of the myokine with bone strength and BMD has been demonstrated in athletes [36] as well as in soccer players [37].

We also reported a positive association between bone status and serum irisin levels in healthy and diabetic children [38, 39]. In our population of pediatric and adult PWS subjects the irisin levels were negatively related to PTH. Consistently, in vitro experiments demonstrated a negative relationship between PTH and irisin, and these findings were further supported by the reduced concentration of the myokine in post-menopausal women with primary hyperparathyroidism with respect to the controls [40]. Although it has been reported that irisin levels were associated with osteoporotic fractures [41], in our study population previous post-traumatic fractures have been described only in five adult PWS patients, and thus it was not possible to evaluate the statistic relevance.

Interestingly, our study revealed that in pediatric PWS the vitamin D levels affected irisin serum concentration. This finding is a novelty in pediatric PWS population as previously we did not find significant correlation between irisin and 25(OH) vitamin D levels in healthy children [38]. The most of our pediatric PWS subjects showed normal vitamin D levels, thus they did not perform vitamin D supplementation, in contrast with our adult PWS population. Indeed, we demonstrated that irisin serum levels were reduced in adult patients without vitamin D supplementation, suggesting that vitamin D supplementation has an important role in regulating irisin levels in adult PWS patients.

Consistently, it has been recently reported that vitamin D supplementation improves irisin levels in obese type 2 diabetic patients [42].

In adult PWS patients we demonstrated a direct link with the age of sex steroid replacement therapy and the age of GH therapy, suggesting the key role of the beginning of the therapy to normalize the levels of the myokine in these subjects. Literature data reported the strict connection between irisin levels and GH as well as the favorable effect of GH replacement therapy on the myokine levels in children with GH deficiency [43].

Interestingly, irisin has been linked to cognitive impairment and neurodegenerative diseases [44], and in adults at risk of dementia its levels correlated with global cognition [45], thus irisin also could represent a serum biomarker of cognitive impairment. Although the results are referred only to 29 adult PWS, we showed that the levels of the myokine positively correlated with total IQ, verbal IQ and performance IQ. However, we did not find the same results for pediatric PWS, thus it is possible that it was evident only in adults, because the IQ impairment was more serious, but also maybe because we had total IQ evaluation only for a restricted number of pediatric subjects.

Consequently, this issue will require future investigations with larger study cohorts.

In conclusion, we did not find different irisin levels in PWS patients compared to matched controls, but we demonstrate possible role of genetic background in PWS on irisin level. Vitamin D supplementation may be key factor in regulating serum irisin levels.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

M. F. Faienza and G. Brunetti contributed equally to this work.

Acknowledgements

TecnoMed Puglia to Maria Grano.

Author contributions

Investigation, methodology, statistics, writing: original draft preparation, GB; clinical settings, writing: original draft preparation, MFF: clinical settings and writing: review and editing GG, DF, AC, PP, AnC; writing: review and editing, SC; conceptualization, project administration, writing: review and editing, MG.

Funding

Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.. This work was supported by TecnoMed Puglia grants to MG.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Research involving human participants and/or animals

All procedures were approved by local institutional review boards.

Informed consent

Written informed consent was obtained from all the legal guardians, and from the patients when applicable, prior to inclusion.

References

1. Butler MG Hartin SN Hossain WA Manzardo AM Kimonis V Dykens E Gold JA Kim SJ Weisensel N Tamura R Miller JL Driscoll DJ Molecular genetic classification in Prader: Willi syndrome: a multisite cohort study J Med Genet 2019 56 3 149 153 10.1136/jmedgenet-2018-105301 29730598 PMC7387113
2. Angulo MA Butler MG Cataletto ME Prader: Willi syndrome: a review of clinical, genetic, and endocrine findings J Endocrinol Investig 2015 38 12 1249 1263 10.1007/s40618-015-0312-9 26062517 PMC4630255
3. de Lind van Wijngaarden RF Festen DA Otten BJ van Mil EG Rotteveel J Odink RJ van Leeuwen M Haring DA Bocca G Mieke Houdijk EC Hokken-Koelega AC Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader: Willi syndrome: a randomized controlled trial J Clin Endocrinol Metab 2009 94 10 3763 3771 10.1210/jc.2009-0270 19622627
4. Edouard T Deal C Van Vliet G Gaulin N Moreau A Rauch F Alos N Muscle-bone characteristics in children with Prader: Willi syndrome J Clin Endocrinol Metab 2012 97 2 E275 281 10.1210/jc.2011-2406 22162467
5. van Mil EG Westerterp KR Gerver WJ Van Marken Lichtenbelt WD Kester AD Saris WH Body composition in Prader: Willi syndrome compared with nonsyndromal obesity: relationship to physical activity and growth hormone function J Pediatr 2001 139 5 708 714 10.1067/mpd.2001.118399 11713451
6. Vestergaard P Kristensen K Bruun JM Ostergaard JR Heickendorff L Mosekilde L Richelsen B Reduced bone mineral density and increased bone turnover in Prader: Willi syndrome compared with controls matched for sex and body mass index: a cross-sectional study J Pediatr 2004 144 5 614 619 10.1016/j.jpeds.2004.01.056 15126995
7. Butler MG Haber L Mernaugh R Carlson MG Price R Feurer ID Decreased bone mineral density in Prader: Willi syndrome: comparison with obese subjects Am J Med Genet 2001 103 3 216 222 10.1002/ajmg.1556 11745993 PMC5157204
8. Hoybye C Hilding A Jacobsson H Thoren M Metabolic profile and body composition in adults with Prader: Willi syndrome and severe obesity J Clin Endocrinol Metab 2002 87 8 3590 3597 10.1210/jcem.87.8.8735 12161480
9. Brunetti G Grugni G Piacente L Delvecchio M Ventura A Giordano P Grano M D'Amato G Laforgia D Crino A Faienza MF Analysis of circulating mediators of bone remodeling in Prader: Willi syndrome Calcif Tissue Int 2018 102 6 635 643 10.1007/s00223-017-0376-y 29353451
10. van Nieuwpoort IC Twisk JWR Curfs LMG Lips P Drent ML Body composition, adipokines, bone mineral density and bone remodeling markers in relation to IGF-1 levels in adults with Prader: Willi syndrome Int J Pediatr Endocrinol 2018 2018 1 10.1186/s13633-018-0055-4 29371863 PMC5771040
11. Colaianni G Cuscito C Mongelli T Pignataro P Buccoliero C Liu P Lu P Sartini L Di Comite M Mori G Di Benedetto A Brunetti G Yuen T Sun L Reseland JE Colucci S New MI Zaidi M Cinti S Grano M The myokine irisin increases cortical bone mass Proc Natl Acad Sci USA 2015 112 39 12157 12162 10.1073/pnas.1516622112 26374841 PMC4593131
12. Colaianni G Mongelli T Cuscito C Pignataro P Lippo L Spiro G Notarnicola A Severi I Passeri G Mori G Brunetti G Moretti B Tarantino U Colucci SC Reseland JE Vettor R Cinti S Grano M Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice Sci Rep 2017 7 1 2811 10.1038/s41598-017-02557-8 28588307 PMC5460172
13. Bostrom P Wu J Jedrychowski MP Korde A Ye L Lo JC Rasbach KA Bostrom EA Choi JH Long JZ Kajimura S Zingaretti MC Vind BF Tu H Cinti S Hojlund K Gygi SP Spiegelman BM A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis Nature 2012 481 7382 463 468 10.1038/nature10777 22237023 PMC3522098
14. Roca-Rivada A Castelao C Senin LL Landrove MO Baltar J Belen Crujeiras A Seoane LM Casanueva FF Pardo M FNDC5/irisin is not only a myokine but also an adipokine PLoS ONE 2013 8 4 e60563 10.1371/journal.pone.0060563 23593248 PMC3623960
15. Jodeiri Farshbaf M Garasia S Moussoki DPK Mondal AK Cherkowsky D Manal N Alvina K Hippocampal injection of the exercise-induced myokine irisin suppresses acute stress-induced neurobehavioral impairment in a sex-dependent manner Behav Neurosci 2020 134 3 233 247 10.1037/bne0000367 32437197
16. Young MF Valaris S Wrann CD A role for FNDC5/Irisin in the beneficial effects of exercise on the brain and in neurodegenerative diseases Prog Cardiovasc Dis 2019 62 2 172 178 10.1016/j.pcad.2019.02.007 30844383 PMC6955153
17. Hirsch HJ Gross I Pollak Y Eldar-Geva T Gross-Tsur V Irisin and the metabolic phenotype of adults with Prader: Willi syndrome PLoS ONE 2015 10 9 e0136864 10.1371/journal.pone.0136864 26334732 PMC4559418
18. Hirsch HJ Gross-Tsur V Sabag Y Nice S Genstil L Benarroch F Constantini N Myokine levels after resistance exercise in young adults with Prader: Willi syndrome (PWS) Am J Med Genet A 2020 182 1 115 121 10.1002/ajmg.a.61391 31692257
19. Mai S Grugni G Mele C Vietti R Vigna L Sartorio A Aimaretti G Scacchi M Marzullo P Irisin levels in genetic and essential obesity: clues for a potential dual role Sci Rep 2020 10 1 1020 10.1038/s41598-020-57855-5 31974460 PMC6978420
20. Holm VA Cassidy SB Butler MG Hanchett JM Greenswag LR Whitman BY Greenberg F Prader: Willi syndrome: consensus diagnostic criteria Pediatrics 1993 91 2 398 402 8424017 PMC6714046
21. Corneli G Di Somma C Baldelli R Rovere S Gasco V Croce CG Grottoli S Maccario M Colao A Lombardi G Ghigo E Camanni F Aimaretti G The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index Eur J Endocrinol 2005 153 2 257 264 10.1530/eje.1.01967 16061832
22. Cole TJ Bellizzi MC Flegal KM Dietz WH Establishing a standard definition for child overweight and obesity worldwide: international survey BMJ 2000 320 7244 1240 1243 10.1136/bmj.320.7244.1240 10797032 PMC27365
23. Kuczmarski RJ Ogden CL Grummer-Strawn LM Flegal KM Guo SS Wei R Mei Z Curtin LR Roche AF Johnson CL CDC growth charts: United States Adv Data 2000 314 1 27 11183293
24. Tanner JM Whitehouse RH Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty Arch Dis Child 1976 51 3 170 179 10.1136/adc.51.3.170 952550 PMC1545912
25. Cutfield WS Jefferies CA Jackson WE Robinson EM Hofman PL Evaluation of HOMA and QUICKI as measures of insulin sensitivity in prepubertal children Pediatr Diabetes 2003 4 3 119 125 10.1034/j.1399-5448.2003.t01-1-00022.x 14655269
26. Carter DR Bouxsein ML Marcus R New approaches for interpreting projected bone densitometry data J Bone Miner Res 1992 7 2 137 145 10.1002/jbmr.5650070204 1570758
27. Crabtree NJ Shaw NJ Bishop NJ Adams JE Mughal MZ Arundel P Fewtrell MS Ahmed SF Treadgold LA Hogler W Bebbington NA Ward KA Team AS Amalgamated reference data for size-adjusted bone densitometry measurements in 3598 children and young adults: the ALPHABET study J Bone Miner Res 2017 32 1 172 180 10.1002/jbmr.2935 27490028 PMC5453244
28. Fintini D Brufani C Grossi A Ubertini G Fiori R Pecorelli L Calzolari A Cappa M Gender differences in bone mineral density in obese children during pubertal development J Endocrinol Investig 2011 34 4 e86 91 10.3275/7265 20855933
29. Kaufman AS Flanagan DP Alfonso VC Mascolo JT Test review: Wechsler Intelligence Scale for Children, fourth edition (WISC-IV) J Psychoeduc Assess 2016 24 3 278 295 10.1177/0734282906288389
30. Matthews J Birch JW The Leiter international performance scale, a suggested instrument for psychological testing of speech and hearing clinic cases J Speech Disord 1949 14 4 318 321 10.1044/jshd.1404.318 15397895
31. Moses JA Jr Pritchard DA Adams RL Neuropsychological information in the Wechsler Adult Intelligence Scale-Revised Arch Clin Neuropsychol 1997 12 2 97 109 10.1093/arclin/12.2.97 14588421
32. Faienza MF Ventura A Lauciello R Crino A Ragusa L Cavallo L Spera S Grugni G Analysis of endothelial protein C receptor gene and metabolic profile in Prader: Willi syndrome and obese subjects Obesity (Silver Spring) 2012 20 9 1866 1870 10.1038/oby.2011.349 22193922
33. Crino A Fintini D Bocchini S Grugni G Obesity management in Prader: Willi syndrome: current perspectives Diabetes Metab Syndr Obes 2018 11 579 593 10.2147/DMSO.S141352 30323638 PMC6175547
34. Cadoudal T Buleon M Sengenes C Diene G Desneulin F Molinas C Eddiry S Conte-Auriol F Daviaud D Martin PG Bouloumie A Salles JP Tauber M Valet P Impairment of adipose tissue in Prader: Willi syndrome rescued by growth hormone treatment Int J Obes (Lond) 2014 38 9 1234 1240 10.1038/ijo.2014.3 24406482
35. Klangjareonchai T Nimitphong H Saetung S Bhirommuang N Samittarucksa R Chanprasertyothin S Sudatip R Ongphiphadhanakul B Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes Int J Endocrinol 2014 2014 261545 10.1155/2014/261545 25276128 PMC4167818
36. Singhal V Lawson EA Ackerman KE Fazeli PK Clarke H Lee H Eddy K Marengi DA Derrico NP Bouxsein ML Misra M Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates PLoS ONE 2014 9 6 e100218 10.1371/journal.pone.0100218 24926783 PMC4057451
37. Colaianni G Notarnicola A Sanesi L Brunetti G Lippo L Celi M Moretti L Pesce V Vicenti G Moretti B Colucci S Grano M Irisin levels correlate with bone mineral density in soccer players J Biol Regul Homeost Agents 2017 31 4 suppl 1 21 28 29181953
38. Colaianni G Faienza MF Sanesi L Brunetti G Pignataro P Lippo L Bortolotti S Storlino G Piacente L D'Amato G Colucci S Grano M Irisin serum levels are positively correlated with bone mineral status in a population of healthy children Pediatr Res 2019 85 4 484 488 10.1038/s41390-019-0278-y 30683930
39. Faienza MF Brunetti G Sanesi L Colaianni G Celi M Piacente L D'Amato G Schipani E Colucci S Grano M High irisin levels are associated with better glycemic control and bone health in children with type 1 diabetes Diabetes Res Clin Pract 2018 141 10 17 10.1016/j.diabres.2018.03.046 29679630
40. Palermo A Sanesi L Colaianni G Tabacco G Naciu AM Cesareo R Pedone C Lelli D Brunetti G Mori G Colucci S Manfrini S Napoli N Grano M A novel interplay between irisin and PTH: from basic studies to clinical evidence in hyperparathyroidism J Clin Endocrinol Metab 2019 104 8 3088 3096 10.1210/jc.2018-02216 30759249
41. Palermo A Strollo R Maddaloni E Tuccinardi D D'Onofrio L Briganti SI Defeudis G De Pascalis M Lazzaro MC Colleluori G Manfrini S Pozzilli P Napoli N Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity Clin Endocrinol (Oxf) 2015 82 4 615 619 10.1111/cen.12672 25400208
42. Safarpour P Daneshi-Maskooni M Vafa M Nourbakhsh M Janani L Maddah M Amiri FS Mohammadi F Sadeghi H Vitamin D supplementation improves SIRT1, Irisin, and glucose indices in overweight or obese type 2 diabetic patients: a double-blind randomized placebo-controlled clinical trial BMC Fam Pract 2020 21 1 26 10.1186/s12875-020-1096-3 32033527 PMC7007689
43. Ciresi A Pizzolanti G Guarnotta V Giordano C Circulating irisin levels in children with GH deficiency before and after 1 year of GH treatment J Clin Endocrinol Metab 2019 104 3 801 808 10.1210/jc.2018-01440 30418584
44. Lourenco MV Frozza RL de Freitas GB Zhang H Kincheski GC Ribeiro FC Goncalves RA Clarke JR Beckman D Staniszewski A Berman H Guerra LA Forny-Germano L Meier S Wilcock DM de Souza JM Alves-Leon S Prado VF Prado MAM Abisambra JF Tovar-Moll F Mattos P Arancio O Ferreira ST De Felice FG Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models Nat Med 2019 25 1 165 175 10.1038/s41591-018-0275-4 30617325 PMC6327967
45. Kuster OC Laptinskaya D Fissler P Schnack C Zugel M Nold V Thurm F Pleiner S Karabatsiakis A von Einem B Weydt P Liesener A Borta A Woll A Hengerer B Kolassa IT von Arnim CAF Novel blood-based biomarkers of cognition, stress, and physical or cognitive training in older adults at risk of dementia: preliminary evidence for a role of BDNF, irisin, and the kynurenine pathway J Alzheimers Dis 2017 59 3 1097 1111 10.3233/JAD-170447 28731451
Publication and source details

Original title: The genetic background and vitamin D supplementation can affect irisin levels in Prader: Willi syndrome

M. F. Faienza; G. Brunetti; G. Grugni; D. Fintini; A. Convertino; P. Pignataro; A. Crinò; S. Colucci; M. Grano

Journal of Endocrinological Investigation · 2021

© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Università degli Studi di Bari Aldo Moro

Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:40:53.316181+00:00

DOI: 10.1007/s40618-021-01533-4 · PMC8421289